UCB and Biogen have announced positive results from their Phase 3 PHOENYCS GO study, showing that dapirolizumab pegol, combined with standard care, significantly improved disease activity in patients with moderate-to-severe systemic lupus erythematosus (SLE) after 48 weeks compared to placebo. This finding offers potential hope for a new treatment option for SLE, a debilitating autoimmune disease.